Experience

Regeneron

• United States
• Biotechnology
• 700 & Above Employee

• Regional Medical Director_EU

  • Jul 2020 - Present

  The Medical Affairs Company on assignment to Regeneron Focused on Hemato-Oncology The Medical Affairs Company on assignment to Regeneron Focused on Hemato-Oncology



Merck Group

• Germany
• Pharmaceutical Manufacturing
• 700 & Above Employee

• MSL Oncology/ Immuno-Oncology

  • Sep 2016 - Jul 2020

  Focused on Head and Neck Cancer, Colorectal Cancer and Merkel Cell Carcinoma (rare tumour). Preparing launch for Renal Cell Carcinoma. Previously involved in Lung Cancer Focused on Head and Neck Cancer, Colorectal Cancer and Merkel Cell Carcinoma (rare tumour). Preparing launch for Renal Cell Carcinoma. Previously involved in Lung Cancer



Eli Lilly and Company

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• ML Diabetes

  • Oct 2014 - Sep 2016

  Focused on Diabetes type 1 and 2 Involved in 3 launches, including the first biosimilar insulin. Focused on Diabetes type 1 and 2 Involved in 3 launches, including the first biosimilar insulin.



Amgen

• United States
• Biotechnology Research
• 700 & Above Employee

• Regional ML Associate Oncology

  • Jan 2014 - Sep 2014

  Role description: 60% field-based + 40% project management Focused on Colorectal Cancer and Biomarkers Role description: 60% field-based + 40% project management Focused on Colorectal Cancer and Biomarkers



Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca

• Spain
• Research Services
• 500 - 600 Employee

• Postdoctoral Researcher

  • Dec 2011 - Dec 2013

  Therapeutic area: Irritable Bowel Syndrome (IBS) Aim: To identify genetic, gender, immunological and molecular basis of the mechanisms connecting environmental determinants (stress and infections) to the development of IBS Therapeutic area: Irritable Bowel Syndrome (IBS) Aim: To identify genetic, gender, immunological and molecular basis of the mechanisms connecting environmental determinants (stress and infections) to the development of IBS



Universitat Autònoma de Barcelona

• Spain
• Higher Education
• 700 & Above Employee

• Postdoctoral Researcher and University Teaching

  • Sep 2009 - Nov 2011

  Therapeutic area: Cancer Aim: To determine whether telomere dysfunction favours the development of polyploid cells through cytokinesis failure, and if the resulting 4N cells have a very unstable genome that is prone to tumourigenesis Teaching Duties in Cell Biology, Physiology and Immunology Department, Faculty of Biosciences, Universidad Autónoma de Barcelona, Spain. - 2010/2011: 232 hours - 2009/2010: 180 hours Therapeutic area: Cancer Aim: To determine whether telomere dysfunction favours the development of polyploid cells through cytokinesis failure, and if the resulting 4N cells have a very unstable genome that is prone to tumourigenesis Teaching Duties in Cell Biology, Physiology and Immunology Department, Faculty of Biosciences, Universidad Autónoma de Barcelona, Spain. - 2010/2011: 232 hours - 2009/2010: 180 hours



Universidad Complutense de Madrid

• Madrid y alrededores, España

• Predoctoral Fellow

  • Sep 2004 - May 2009

  Therapeutic area: Lung cancer Aim: To evaluate the prognostic impact of telomere dysfunction and its relationship with DNA repair systems in non-small cell lung cancer (NSCLC) Therapeutic area: Lung cancer Aim: To evaluate the prognostic impact of telomere dysfunction and its relationship with DNA repair systems in non-small cell lung cancer (NSCLC)



Institute for Human Genetics

• Newcastle upon Tyne, UK

• Predoctoral Fellow

  • Oct 2007 - Dec 2007